DOCSLIB.ORG

April 2020 Sanctions List Full

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

GLOBAL LIST OF INELIGIBLE PERSONS Period of Date of Discipline Date of Ineligibility Lifetime Infraction Name Nationality Role Sex Discipline 2 Sanction Disqualification ADRV Rules ADRV Notes Description Birth 1 Infraction until Ban? Type of results ABAKUMOVA, Maria 15/01/1986 RUS athlete F Javelin Throws 21/08/2008 4 years 17/05/2020 From 21.08.08 to No Doping Presence,Use Dehydrochlormethyltestost In competition test, XXIX Olympic ineligibility 20.08.12 erone games, Beijing, CHN ABDOSH, Ali 25/08/1987 ETH athlete M Long Distance 24/12/2017 4 years 04/02/2022 Since 24-12-2017 No Doping Presence,Use Salbutamol In competition test, 2017 Baoneng (3000m+) ineligibility Guangzhou Huangpu Marathon , Guangzhou, CHN ABDUL SHAHID (NASERA), Haidar 13/01/1981 IRQ athlete M Throws 08/03/2019 4 years 05/05/2023 Since 08.03.19 No Doping Presence,Use Metandienone In competition test, Iraqi ineligibility Championships, Baghdad, IRQ ACHERKI, Mounir 09/02/1981 FRA athlete M 1500m Middle Distance 01/01/2014 4 years 15/04/2021 Since 01-01-2014 No Doping Use,Possessio Use or Attempted Use by an IAAF Rule 32.2(b) Use of a prohibited (800m-1500m) ineligibility n Athlete of a Prohibited substance Substance or a Prohibited IAAF Rule 32.2(f) Possession of a Method, Possession of a prohibited substance Prohibited Substance or a Prohibited Method ADAMCHUK, Mariya 29/05/2000 UKR athlete F Long Jump Jumps 03/06/2018 4 years 16/08/2022 Since 03.06.18 No Doping Presence,Use Trenbolone, DMBA & ICT, Ukrainian club U20 ineligibility Methylhexaneamine Championships', Lutsk, UKR ADEKOYA, Kemi 16/01/1993 BRN athlete F 400m Sprints (400m or 24/08/2018 4 years 25/11/2022 Since 24.08.18 No Doping Presence,Use Stanozolol Out-of-competition test, Jakarta, IDN Hurdles less) ineligibility ADELOYE, Tosin 07/02/1996 NGR athlete F 400m Sprints (400m or 24/07/2015 8 years 23/07/2023 Since 24-07-2015 No Doping Presence,Use Exogenous Steroids In competition test, Warri Relays - less) ineligibility (2nd CAA Super Grand Prix , Warri, NGR ADRV) ADLI SAIFUL, Muh. Syazrul 17/02/2001 MAS athlete M Sprints (400m or 18/08/2019 4 years 12/12/2023 Since 18.08.19 No Doping Presence,Use Methasterone & In competition test, 96th Malaysian less) ineligibility Oxymetholone Athletics Championship 2019, Kuala Lumpur, MAS ADOK, Roland 29/10/1984 HUN athlete M Long Distance 01/05/2019 2 years 22/05/2021 Since 01.05.19 No Doping Presence,Use Clenbuterol ICT, Hungary 50km ultra running (3000m+) ineligibility Championships 2019, Budakalasz, HUN AGAFONOVA KHANAFEYEVA, Gulfiya RUS athlete F Hammer Throws 8 years 05/01/2025 From 15.07.12 - No Doping Presence,Use Dehydrochlormethyltestost (Retesting) In competition test, XXX ineligibility 06.08.14 erone; Use Olympic Games, London, GBR; McLaren evidence AHMED, Belal 20/11/1986 EGY athlete M Long Distance 27/09/2019 4 years 03/12/2023 Since 27.09.19 No Doping Presence,Use EPO Out-of-competition test, Berlin, GER (3000m+) ineligibility AKKOYUN, Mehmet 28/02/1989 TUR athlete M Long Distance 11/08/2014 4 years 07/02/2021 Since 11-08-2014 No Doping Use Athlete Biological Passport Athlete Biological Passport Case (3000m+) ineligibility AL ABBODY, Karar A.M. 08/08/1986 IRQ athlete M 400m Sprints (400m or 10/10/2015 4 years 14/02/2020 Since 10-10-2015 No Doping Presence,Use Metandienone Out of competition test, IRQ less) ineligibility Al BISHI, Saad Musleh 02/05/1986 KSA athlete M Shot Put Throws 06/02/2016 4 years 02/03/2020 Since 05-02-2016 No Doping Presence,Use Amphetamine In competition test, Federation Cup ineligibility , Jeddah, RSA AL KHALIFA, Abdullah (Hussain) 16/01/1994 KSA athlete M Triple Jump Jumps 04/03/2017 4 years 03/04/2021 Since 4.3.17 No Doping Presence,Use Stanozolol In competition test, Kingdom 1st ineligibility Class Championships Jeddah, KSA AL-HASAN, Mohammad Yaseen 30/08/1993 KSA athlete M 400m Sprints (400m or 05/02/2016 4 years 16/09/2021 Since 05-02-2016 No Doping Presence,Use Oxandrolone In competition test, Federation Cup, less) ineligibility Qatif, KSA AL-MEQBALI, Rashed Saif 24/08/1978 UAE athlete M Shot Put Throws 31/05/2014 8 years 30/05/2022 Since 31-05-2014 No Doping Presence,Use Stanozolol Out of competition test, Dubai, UAE ineligibility AL-YAMI, Nawaf Ahmed 01/07/1992 KSA athlete M High Jump Jumps 06/02/2016 4 years 29/02/2020 Since 06-02-2016 No Doping Presence,Use Amphetamine In competition test, Federation Cup ineligibility , Qatif, RSA ALAOUI SELSOULI, Mariem 08/07/1984 MAR athlete F 1500m Middle Distance 06/07/2012 8 years 24/07/2020 Since 06-07-2012 No Doping Presence,Use Furosemide In competition test, Meeting Areva , (800m-1500m) ineligibility Paris-St-Denis, FRA ALI, Mohammad 01/01/1986 IRQ athlete M Sprints (400m or 10/10/2015 4 years 14/02/2020 Since 14-02-2013 No Doping Presence,Use Metandienone less) ineligibility ALIKULOV, Toshali 12/07/1999 KAZ athlete M Long Distance 05/05/2018 4 years 11/06/2022 Since 05-05-2018 No Doping Presence,Use Meldonium In competition test, Kazakhstan (3000m+) ineligibility Junior Championships , Shymkent, KAZ ALMSHDINY HAMID, Zenia 11/04/1988 IRQ athlete F Combined Events 07/03/2019 8 years 29/07/2027 Since 07.03.19 No Doping Evasion,Refusa Refusal In competition test, Iraqi ineligibility l and or Failure Championships, Baghdad, IRQ to Submit ALMUDI CID, Cristobel 02/03/1979 ESP athlete M Hammer Throws 14/05/2016 4 years 12/07/2020 Since 14-05-2016 No Doping Presence,Use Stanozolol & Nandrolone In competition test Campeonato ineligibility metabolites Espana Veteranos Madrid, ESP 29.04.2020 www.athleticsintegrity.org 1 GLOBAL LIST OF INELIGIBLE PERSONS Period of Date of Discipline Date of Ineligibility Lifetime Infraction Name Nationality Role Sex Discipline 2 Sanction Disqualification ADRV Rules ADRV Notes Description Birth 1 Infraction until Ban? Type of results ALOTAIBI, Mukhlid 20/06/1976 KSA athlete M 5000m Long Distance 19/07/2016 4 years 19/10/2020 Since 19-07-2016 No Doping Presence,Use, CERA, Evading, Refusing or IAAF Rule 32.2. (c) Evading sample (3000m+) ineligibility Evasion,Refusa Failing to Submit to Sample collection, Ifrane, MAR l and or Failure Collection Out of competition test, Ifrane, MAR to Submit & Rio de Janeiro, BRA ALSALEH, Monira 18/05/1985 SYR athlete F 200m Sprints (400m or 26/02/2010 Lifetime ban Since 26-02-10 Yes Doping Presence,Use Stanozolol and Metenolone In competition test, 'Asian Indoor less) (2nd ADRV) Championships', Tehran IRI AMICHE, Hicham 05/06/1991 ALG athlete M Middle Distance 13/05/2018 2 years 13/11/2020 Since 13.05.18 No Doping Presence,Use Tamoxifen In competition test, Meeting elite de (800m-1500m) ineligibility Montgeron, Essone, FRA ANANENKO, Anis 29/11/1985 BLR athlete M 400m Sprints (400m or 08/08/2012 From 08.08.12 to No Doping Presence,Use Dehydrochloromethyltestos In competition test, XXX Olympic less) 27.05.15 terone Games, London, GBR ANDREAS, Jeromy 28/02/1992 RSA athlete M Long Distance 08/09/2018 4 years 29/10/2022 Since 08-09-2018 No Doping Presence,Use 1-Testosterone (3000m+) ineligibility ANDREEV, Andrian 24/07/1977 BUL athlete M Hammer Throws 27/02/2008 Lifetime ban Since 27-02-2008 Yes Doping Presence,Use Metenolone Out of competition testing by the (2nd ADRV) Bulgarian Athletic Federation ANNANI, Adil 30/06/1980 MAR athlete M Marathon Long Distance 04/11/2011 4 years 20/06/2020 Since 04-11-2011 No Doping Use Athlete Biological Passport Athlete Biological Passport Case (3000m+) ineligibility ANTUNES, Luis Paolo 28/11/1980 BRA athlete M Race Walk Long Distance 27/09/2015 8 years 26/09/2023 Since 27.09.15 No Doping Presence,Use Stanozolol In competition test, Maraton (3000m+) ineligibility Internacional SESCPR , Foz do Iguacu, BRA APHANE, Reneilwe 24/08/1990 RSA athlete M Triple Jump Jumps 31/01/2018 3 years and 6 27/08/2021 Since 31.01.18 No Doping Presence,Use Dehydrochloromethyltestos Out-of-competition test, months terone, Clomiphene, Soshanguve, RSA ineligibility GW1516 ARUMUGAM, Karthik 02/06/1992 IND athlete M Long Jump Jumps 30/12/2017 2 years 03/04/2020 Since 30.12.17 No Doping Presence,Use Methylhexaneamine In competition test, 66th All India ineligibility Police Athletics Championship, Dehradun, IND ARZHANGNEZHAD, Ali 07/01/1999 IRI athlete M Sprints (400m or 11/01/2018 4 years 12/03/2022 Since 11-01-2018 No Doping Presence,Use Stanozolol In competition test, National indoor less) ineligibility athletics championships, Tehran, IRN ASLAN, Veysi 23/02/1984 TUR athlete M Long Distance 09/10/2016 8 years 18/06/2025 From 09.10.16 No Doping Presence,Use EPO In competition, in International (3000m+) ineligibility (2nd Darica Half Marathon , Darica, TUR ADRV) ASSILA, Anouar 01/01/1983 FRA athlete M Long Distance 26/10/2014 4 years 18/09/2021 On 26.10.14 and No Doping Use Athlete Biological Passport Athlete Biological Passport Case (3000m+) ineligibility 20.11.16 AVRAMENKO, Roman 23/03/1988 RUS athlete M Javelin Throws 30/07/2015 8 years 29/08/2023 Since 30.07.15 No Doping Presence,Use Dehydrochloromethyltestos Out-of competition test, Kirovske ineligibility (2nd terone ADRV) AYDEMIR, Mazlum 19/07/1983 TUR athlete M Long Distance 29/08/2015 A life-time Since 29-08-2015 Yes Doping Presence,Use Erythropoietin In competition test, track & field 1st (3000m+) ineligibility to 20-02-17 league final , Cankiri, TUR & '60th Omer Besim Cross-Country Race' in Istanbul, TUR AYHAN-KOP, Surreya 06/09/1978 TUR athlete F 1500m Middle Distance 08/09/2007 Lifetime ban Since 08-09-07 Yes Doping Presence,Use Stanozolol Out of competition (800m-1500m) (2nd ADRV) AZIKE, Henry 07/01/1989 NGR athlete M 100m Sprints (400m or 05/12/2012
Recommended publications
  • The 2021 List of Pharmacological Classes of Doping Agents and Doping Methods

    The 2021 List of Pharmacological Classes of Doping Agents and Doping Methods

    BGBl. III - Ausgegeben am 8. Jänner 2021 - Nr. 1 1 von 23 The 2021 list of pharmacological classes of doping agents and doping methods www.ris.bka.gv.at BGBl. III - Ausgegeben am 8. Jänner 2021 - Nr. 1 2 von 23 www.ris.bka.gv.at BGBl. III - Ausgegeben am 8. Jänner 2021 - Nr. 1 3 von 23 THE 2021 PROHIBITED LIST WORLD ANTI-DOPING CODE DATE OF ENTRY INTO FORCE 1 January 2021 Introduction The Prohibited List is a mandatory International Standard as part of the World Anti-Doping Program. The List is updated annually following an extensive consultation process facilitated by WADA. The effective date of the List is 1 January 2021. The official text of the Prohibited List shall be maintained by WADA and shall be published in English and French. In the event of any conflict between the English and French versions, the English version shall prevail. Below are some terms used in this List of Prohibited Substances and Prohibited Methods. Prohibited In-Competition Subject to a different period having been approved by WADA for a given sport, the In- Competition period shall in principle be the period commencing just before midnight (at 11:59 p.m.) on the day before a Competition in which the Athlete is scheduled to participate until the end of the Competition and the Sample collection process. Prohibited at all times This means that the substance or method is prohibited In- and Out-of-Competition as defined in the Code. Specified and non-Specified As per Article 4.2.2 of the World Anti-Doping Code, “for purposes of the application of Article 10, all Prohibited Substances shall be Specified Substances except as identified on the Prohibited List.
  • Androgen Receptor: a Complex Therapeutic Target for Breast Cancer

    Androgen Receptor: a Complex Therapeutic Target for Breast Cancer

    cancers Review Androgen Receptor: A Complex Therapeutic Target for Breast Cancer Ramesh Narayanan 1 and James T. Dalton 2,* 1 Department of Medicine, University of Tennessee Health Science Center, Memphis, TN 38103, USA; [email protected] 2 College of Pharmacy, University of Michigan, Ann Arbor, MI 48109, USA * Correspondence: [email protected] Academic Editor: Emmanuel S. Antonarakis Received: 28 September 2016; Accepted: 23 November 2016; Published: 2 December 2016 Abstract: Molecular and histopathological profiling have classified breast cancer into multiple sub-types empowering precision treatment. Although estrogen receptor (ER) and human epidermal growth factor receptor (HER2) are the mainstay therapeutic targets in breast cancer, the androgen receptor (AR) is evolving as a molecular target for cancers that have developed resistance to conventional treatments. The high expression of AR in breast cancer and recent discovery and development of new nonsteroidal drugs targeting the AR provide a strong rationale for exploring it again as a therapeutic target in this disease. Ironically, both nonsteroidal agonists and antagonists for the AR are undergoing clinical trials, making AR a complicated target to understand in breast cancer. This review provides a detailed account of AR’s therapeutic role in breast cancer. Keywords: androgen receptor; breast cancer; selective androgen receptor modulator (SARM); estrogen receptor; triple-negative breast cancer (TNBC) 1. Introduction Over 240,000 women will develop breast cancer and ~40,000 will die from the disease in the United States in 2016 [1]. Globally, about 1.7 million women were diagnosed with breast cancer in 2012, emphasizing the urgent need for effective and safe therapeutic approaches [2].
  • Cancer Palliative Care and Anabolic Therapies

    Cancer Palliative Care and Anabolic Therapies

    Cancer Palliative Care and Anabolic Therapies Aminah Jatoi, M.D. Professor of Oncology Mayo Clinic, Rochester, Minnesota USA • 2 Androgens • Creatine • Comments von Haehling S, et al, 2017 Oxandrolone: androgen that causes less virilization oxandrolone RANDOMIZE megestrol acetate #1: Oxandrolone (Lesser, et al, ASCO abstract 9513; 2008) • N=155 patients receiving chemotherapy • oxandrolone (10 mg twice a day x 12 weeks) versus megestrol acetate (800 mg/day x 12 weeks) • oxandrolone led to – a non-statistically significant increase in lean body mass (bioelectrical impedance) at 12 weeks (2.67 versus 0.82 pounds with megestrol acetate, p = 0.12), but – a decrease in overall weight as compared with megestrol acetate (-3.3 versus +5.8 pounds, respectively). • more oxandrolone patients dropped out prior to completing 12 weeks (63% versus 39 %). #2: Oxandrolone (von Roenn, et al, ASCO, 2003) • N=131 • Single arm • 81% of patients gained/maintained weight • Safe (PRIMARY ENDPOINT): 19% edema; 18% dyspnea; mild liver function test abnormalities #3: Oxandrolone: placebo controlled trial • results unknown SUMMARY OF OXANDROLONE: • Multiple studies (not yet peer-reviewed) • Hints of augmentation of lean tissue • High drop out in the phase 3 oxandrolone arm raises concern Enobosarm: selective androgen receptor modulator (less virilizing) ENOBOSARM RANDOMIZE* PLACEBO *All patients had non-small cell lung cancer, and chemotherapy was given concomittantly. percentage of subjects at day 84 with stair climb power change >=10% from their baseline value percentage of subjects at day 84 with lean body mass change >=0% from their baseline value SUMMARY OF ENOBOSARM: • Leads to incremental lean body mass, but functionality not demonstrated • Pivotal registration trial (not yet peer- reviewed (but FDA-reviewed….)) • 2 Androgens • Creatine • Comments Creatine: an amino acid derivative This study was funded by R21CA098477 and the Alliance for Clinical Trials NCORP grant.
  • EDITION 3 QUALIFIERS Race Dates Are Displayed in US Format and Correct As of 16 December 2020

    EDITION 3 QUALIFIERS Race Dates Are Displayed in US Format and Correct As of 16 December 2020

    EDITION 3 QUALIFIERS Race dates are displayed in US format and correct as of 16 December 2020. Dates subject to change. Race Name City Country Date Xiamen Marathon Xiamen China 1/3/21 Egyptian Marathon Luxor City Egypt 1/15/21 Louisiana Marathon Baton Rouge USA 1/17/21 Buriram Marathon Buriram Thailand 1/24/21 Funchal Marathon Funchal Portugal 1/24/21 Marrakech International Marathon Marrakesh Morocco 1/31/21 Gulf Bank 642 Marathon Kuwait City Kuwait 2/6/21 Florida Marathon Melbourne USA 2/7/21 Maratona di San Valentino Terni Italy 2/7/21 AU Bank Jaipur Marathon Jaipur India 2/14/21 Zurich Seville Marathon Seville Spain 2/14/21 Tel Aviv Samsung Marathon Tel Aviv Israel 2/19/21 Mississippi Blues Marathon Jackson USA 2/27/21 Techcombank Ho Chi Minh City International Ho Chi Minh City Vietnam 2/28/21 Marathon Carthage Marathon Carthage Tunisia 2/28/21 Lake Biwa Mainichi Marathon Shiga Japan 2/28/21 Kilimanjaro Marathon Moshi Tanzania 2/28/21 Split Marathon Split Croatia 2/28/21 Maratón BP Castellón Castellon Spain 2/28/21 Publix Atlanta Marathon Atlanta USA 2/28/21 Little Rock Marathon Little Rock USA 3/7/21 Erlanger Chattanooga Marathon Weekend Chattanooga USA 3/7/21 NaFplio Marathon Nafplio Greece 3/7/21 Bila Tserkva Marathon Bila Tserkva Ukraine 3/10/21 Nagoya Women's Marathon Nagoya Japan 3/14/21 Kingston City Marathon Kingston Jamaica 3/14/21 Chengdu Panda Marathon Chengdu China 3/21/21 Acea Run Rome the Marathon Rome Italy 3/21/21 Techcombank Ha Noi Marathon Hanoi Vietnam 3/28/21 Cartago Marathon Cartago Costa Rica 3/28/21 Charlottesville
  • Drug Testing Program

    Drug Testing Program

    DRUG TESTING PROGRAM Copyright © 2021 CrossFit, LLC. All Rights Reserved. CrossFit is a registered trademark ® of CrossFit, LLC. 2021 DRUG TESTING PROGRAM 2021 DRUG TESTING CONTENTS 1. DRUG-FREE COMPETITION 2. ATHLETE CONSENT 3. DRUG TESTING 4. IN-COMPETITION/OUT-OF-COMPETITION DRUG TESTING 5. REGISTERED ATHLETE TESTING POOL (OUT-OF-COMPETITION DRUG TESTING) 6. REMOVAL FROM TESTING POOL/RETIREMENT 6A. REMOVAL FROM TESTING POOL/WATCH LIST 7. TESTING POOL REQUIREMENTS FOLLOWING A SANCTION 8. DRUG TEST NOTIFICATION AND ADMINISTRATION 9. SPECIMEN ANALYSIS 10. REPORTING RESULTS 11. DRUG TESTING POLICY VIOLATIONS 12. ENFORCEMENT/SANCTIONS 13. APPEALS PROCESS 14. LEADERBOARD DISPLAY 15. EDUCATION 16. DIETARY SUPPLEMENTS 17. TRANSGENDER POLICY 18. THERAPEUTIC USE EXEMPTION APPENDIX A: 2020-2021 CROSSFIT BANNED SUBSTANCE CLASSES APPENDIX B: CROSSFIT URINE TESTING PROCEDURES - (IN-COMPETITION) APPENDIX C: TUE APPLICATION REQUIREMENTS Drug Testing Policy V4 Copyright © 2021 CrossFit, LLC. All Rights Reserved. CrossFit is a registered trademark ® of CrossFit, LLC. [ 2 ] 2021 DRUG TESTING PROGRAM 2021 DRUG TESTING 1. DRUG-FREE COMPETITION As the world’s definitive test of fitness, CrossFit Games competitions stand not only as testaments to the athletes who compete but to the training methodologies they use. In this arena, a true and honest comparison of training practices and athletic capacity is impossible without a level playing field. Therefore, the use of banned performance-enhancing substances is prohibited. Even the legal use of banned substances, such as physician-prescribed hormone replacement therapy or some over-the-counter performance-enhancing supplements, has the potential to compromise the integrity of the competition and must be disallowed. With the health, safety, and welfare of the athletes, and the integrity of our sport as top priorities, CrossFit, LLC has adopted the following Drug Testing Policy to ensure the validity of the results achieved in competition.
  • UFC PROHIBITED LIST Effective June 1, 2021 the UFC PROHIBITED LIST

    UFC PROHIBITED LIST Effective June 1, 2021 the UFC PROHIBITED LIST

    UFC PROHIBITED LIST Effective June 1, 2021 THE UFC PROHIBITED LIST UFC PROHIBITED LIST Effective June 1, 2021 PART 1. Except as provided otherwise in PART 2 below, the UFC Prohibited List shall incorporate the most current Prohibited List published by WADA, as well as any WADA Technical Documents establishing decision limits or reporting levels, and, unless otherwise modified by the UFC Prohibited List or the UFC Anti-Doping Policy, Prohibited Substances, Prohibited Methods, Specified or Non-Specified Substances and Specified or Non-Specified Methods shall be as identified as such on the WADA Prohibited List or WADA Technical Documents. PART 2. Notwithstanding the WADA Prohibited List and any otherwise applicable WADA Technical Documents, the following modifications shall be in full force and effect: 1. Decision Concentration Levels. Adverse Analytical Findings reported at a concentration below the following Decision Concentration Levels shall be managed by USADA as Atypical Findings. • Cannabinoids: natural or synthetic delta-9-tetrahydrocannabinol (THC) or Cannabimimetics (e.g., “Spice,” JWH-018, JWH-073, HU-210): any level • Clomiphene: 0.1 ng/mL1 • Dehydrochloromethyltestosterone (DHCMT) long-term metabolite (M3): 0.1 ng/mL • Selective Androgen Receptor Modulators (SARMs): 0.1 ng/mL2 • GW-1516 (GW-501516) metabolites: 0.1 ng/mL • Epitrenbolone (Trenbolone metabolite): 0.2 ng/mL 2. SARMs/GW-1516: Adverse Analytical Findings reported at a concentration at or above the applicable Decision Concentration Level but under 1 ng/mL shall be managed by USADA as Specified Substances. 3. Higenamine: Higenamine shall be a Prohibited Substance under the UFC Anti-Doping Policy only In-Competition (and not Out-of- Competition).
  • Disposition of T Oxic Drugs and Chemicals

    Disposition of T Oxic Drugs and Chemicals

    Disposition of Toxic Drugs and Chemicals in Man, Eleventh Edition Eleventh Edition in Man and Chemicals Drugs Toxic Disposition of The purpose of this work is to present in a single convenient source the current essential information on the disposition of the chemi- cals and drugs most frequently encountered in episodes of human poisoning. The data included relate to the body fluid concentrations of substances in normal or therapeutic situations, concentrations in fluids and tissues in instances of toxicity and the known metabolic fate of these substances in man. Brief mention is made of specific analytical procedures that are applicable to the determination of each substance and its active metabolites in biological specimens. It is expected that such information will be of particular interest and use to toxicologists, pharmacologists, clinical chemists and clinicians who have need either to conduct an analytical search for these materials in specimens of human origin or to interpret 30 Amberwood Parkway analytical data resulting from such a search. Ashland, OH 44805 by Randall C. Baselt, Ph.D. Former Director, Chemical Toxicology Institute Bookmasters Foster City, California HARD BOUND, 7” x 10”, 2500 pp., 2017 ISBN 978-0-692-77499-1 USA Reviewer Comments on the Tenth Edition “...equally useful for clinical scientists and poison information centers and others engaged in practice and research involving drugs.” Y. Caplan, J. Anal. Tox. “...continues to be an invaluable and essential resource for the forensic toxicologist and pathologist.” D. Fuller, SOFT ToxTalk “...has become an essential reference book in many laboratories that deal with clinical or forensic cases of poisoning.” M.
  • Annual Report 2016

    Annual Report 2016

    ANNUAL REPORT 2016 Facts and Introduction Corporate Manufacturing Products Markets Personnel Communication Figures speech Governance Policy Policy CONTENTS Facts and Figures Introduction speech by the Chairmen of the Council and Board Corporate Governance Manufacturing Products Markets Personnel Policy Communication Policy “Grindeks” Group – JSC “Grindeks” and five its subsidiary companies – JSC “Tallin Pharmaceutical plant” in Estonia, JSC “Kalceks” in Latvia, “Namu Apsaimniekošanas projekti” Ltd in Latvia, “Grindeks Rus” Ltd in Russia and “HBM Pharma” Ltd in Slovakia Core business – research, development, manufacturing and sales of original products, generics and active pharmaceutical ingredients Turnover – 105.4 million euros Net profit – 9.5 million euros Investments – 5.5 million euros Gross profit margin – 55% Net profit margin – 9% Export volume – 95.7 million euros Export countries – 71 Main markets – European Union, Russia and other CIS countries, USA, Canada, Japan and Vietnam FACTS AND FIGURES OF 2016 ANNUAL REPORT 2016 SALES OF FINAL DOSAGE FORMS Final dosage forms sales volume – 97.5 million euros Sales volume in Russia, other CIS countries and Georgia – 58.2 million euros Sales volume in the Baltic States and other countries – 39.3 million euros TOP products – meldonium, tegafurum, zopiclone, risperidone, ipidacrine, oxytocin, pain relief ointments and dietary supplementsApilak-Grindeks. SALES OF ACTIVE PHARMACEUTICAL INGREDIENTS (API'S) Sales volume of API's – 6.3 million euros Offered 17 API's The most demanded API's of “Grindeks” – oxytocin, zopiclone, droperidol, detomidine, and pimobendan. QUALITY AND ENVIRONMENTAL CONTROL “Good Manufacturing Practice” certificates for manufacturing of final dosage forms and active pharmaceutical ingredients ISO 9001; ISO 14001; LVS OHSAS 18001 certificates Russian ГОСТ ISO 9001-2011 certificate LVS EN ISO 50001:2012 Energy management certificate FACTS AND FIGURES OF 2016 ANNUAL REPORT 2016 achievements, the greater our ability to invest in further business growth.
  • CAS Number Index

    CAS Number Index

    2334 CAS Number Index CAS # Page Name CAS # Page Name CAS # Page Name 50-00-0 905 Formaldehyde 56-81-5 967 Glycerol 61-90-5 1135 Leucine 50-02-2 596 Dexamethasone 56-85-9 963 Glutamine 62-44-2 1640 Phenacetin 50-06-6 1654 Phenobarbital 57-00-1 514 Creatine 62-46-4 1166 α-Lipoic acid 50-11-3 1288 Metharbital 57-22-7 2229 Vincristine 62-53-3 131 Aniline 50-12-4 1245 Mephenytoin 57-24-9 1950 Strychnine 62-73-7 626 Dichlorvos 50-23-7 1017 Hydrocortisone 57-27-2 1428 Morphine 63-05-8 127 Androstenedione 50-24-8 1739 Prednisolone 57-41-0 1672 Phenytoin 63-25-2 335 Carbaryl 50-29-3 569 DDT 57-42-1 1239 Meperidine 63-75-2 142 Arecoline 50-33-9 1666 Phenylbutazone 57-43-2 108 Amobarbital 64-04-0 1648 Phenethylamine 50-34-0 1770 Propantheline bromide 57-44-3 191 Barbital 64-13-1 1308 p-Methoxyamphetamine 50-35-1 2054 Thalidomide 57-47-6 1683 Physostigmine 64-17-5 784 Ethanol 50-36-2 497 Cocaine 57-53-4 1249 Meprobamate 64-18-6 909 Formic acid 50-37-3 1197 Lysergic acid diethylamide 57-55-6 1782 Propylene glycol 64-77-7 2104 Tolbutamide 50-44-2 1253 6-Mercaptopurine 57-66-9 1751 Probenecid 64-86-8 506 Colchicine 50-47-5 589 Desipramine 57-74-9 398 Chlordane 65-23-6 1802 Pyridoxine 50-48-6 103 Amitriptyline 57-92-1 1947 Streptomycin 65-29-2 931 Gallamine 50-49-7 1053 Imipramine 57-94-3 2179 Tubocurarine chloride 65-45-2 1888 Salicylamide 50-52-2 2071 Thioridazine 57-96-5 1966 Sulfinpyrazone 65-49-6 98 p-Aminosalicylic acid 50-53-3 426 Chlorpromazine 58-00-4 138 Apomorphine 66-76-2 632 Dicumarol 50-55-5 1841 Reserpine 58-05-9 1136 Leucovorin 66-79-5
  • LIGANDROL Comprometimento Ósseo

    LIGANDROL Comprometimento Ósseo

    Apresenta ação anabólica com poucos efeitos androgênicos e virilizantes Auxilia no tratamento de condições onde há perda de massa muscular e LIGANDROL comprometimento ósseo Promove a hipertrofia e aumenta a força muscular O QUE É? RA especialmente pelos ligantes exógenos, como os esteróides anabolizantes androgênicos (EAA), pode estar envolvida com o O ligandrol, também conhecido como anabolicum ou LGD- desenvolvimento de patologias na próstata, coração e fígado. Isto 4033, é caracterizado como um modulador seletivo do receptor porque, o receptor RA está expresso em diferentes tecidos, o que de androgênio (SARM) de estrutura não esteroidal que atua de de certa forma limita o uso terapêutico dos EAA em condições forma seletiva sobre os tecidos que expressam os receptores mais específicas como sarcopenia, caquexia associada à doenças androgênicos (RA). Por sua especificidade e alta afinidade ao como câncer, osteoporose e hipogonadismo. RA, tem sido demonstrado que o ligandrol apresenta atividade anabólica no músculo e anti – reabsortiva e anabólica no tecido Com o intuito de contornar possíveis limitações que resultam da ósseo, ao passo que apresenta efeitos androgênicos mínimos ativação global dos RA, os moduladores seletivos de receptores sobre próstata, couro cabeludo e pele. 1 androgênicos, também conhecidos como SARMs, do inglês Selective Androgen Receptor Modulators, tem sido objeto de Os SARMs como o ligandrol e ostarine, têm sido avaliados como estudo uma vez que parecem ativar os RA de maneira específica uma alternativa eficaz e segura para o tratamento de perda e seletiva em determinados tecidos, reduzindo também a de massa muscular associada ao envelhecimento e a outras ocorrência de efeitos colaterais indesejados.
  • Anti-Cytokines in the Treatment of Cancer Cachexia

    Anti-Cytokines in the Treatment of Cancer Cachexia

    79 Review Article Anti-cytokines in the treatment of cancer cachexia Bernard Lobato Prado1, Yu Qian2 1Department of Oncology and Hematology, Hospital Israelita Albert Einstein, Sao Paulo, Brazil; 2Department of Thoracic Oncology, Hubei Cancer Hospital, Wuhan 430070, China Contributions: (I) Conception and design: All authors; (II) Administrative support: None; (III) Provision of study materials or patients: None; (IV) Collection and assembly of data: None; (V) Data analysis and interpretation: None; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors. Correspondence to: Bernard Prado, MD. Department of Oncology and Hematology, Hospital Israelita Albert Einstein, Albert Einstein Av. 627, Sao Paulo 05652-900, Brazil. Email: [email protected]. Abstract: Cancer-related cachexia (CRC) is a multidimensional, frequent and devastating syndrome. It is mainly characterized by a loss of skeletal muscle tissue, accompanied or not by a loss of adipose tissue that leads to impaired functionality, poor quality of life, less tolerability to cancer-directed therapies, high levels of psychosocial distress, and shorter survival. Despite its clinical importance, there is a lack of effective pharmacological therapies to manage CRC. Pro-cachectic cytokines have been shown to play a critical role in its pathogenesis, providing the conceptual basis for testing anti-cytokine drugs to treat this paraneoplastic syndrome. The aim of this review was to examine the current evidence on anti-cytokines in the treatment of CRC. Several anti-cytokine agents targeting one or more molecules (i.e., TNF-alpha, IL-1 alpha, IL- 6, and others) have been investigated in clinical trials for the treatment of CRC, mainly in phase I and II studies.
  • Maciej Łuczak Oszustwo Dopingowe W Sporcie Wyczynowym

    Maciej Łuczak Oszustwo Dopingowe W Sporcie Wyczynowym

    ROZPRAWY NAUKOWE Akademii Wychowania Fizycznego we Wrocławiu 2018, 60, 118 – 134 Maciej Łuczak Akademia Wychowania Fizycznego w Poznaniu OSZUSTWO DOPINGOWE W SPORCIE WYCZYNOWYM WśRÓD KOBIET W LATACH 1950–2017 Cel badań. W artykule przedstawiono zjawisko dopingu kobiet w sporcie w XX i XXI w. Wśród sportsmenek sztuczne wspomaganie wykryto w latach 50. XX w. W niektórych krajach powstał system maskowania dopingu przez władze państwowe. Doświadczenie w zakresie opracowywania i podawania leków wspomagających miały laboratoria antydopingowe, m.in. w Kreischa w NRD. Stosowanie niedozwolonych praktyk ukazano na przykładzie NRD, RFN, ZSRR, Chin, USA, Kenii i Polski. Materiał i metody. Materiał badawczy został zinterpretowany przy użyciu metod stoso- wanych w naukach historycznych: indukcyjnej, dedukcyjnej, komparatystycznej i analizy litera- tury specjalistycznej. Do sformułowania ostatecznych wniosków wykorzystano metodę syntezy. Wyniki. Praktyki dopingowe miały miejsce w wielu krajach. Od 1956 r. notuje się stosowanie wspomagania organizmów sportsmenek za pomocą testosteronu. Z czasem doszły bardziej udo- skonalone niedozwolone środki oraz metody, takie jak np. doping ciążowy. Najbardziej zorganizo- wany doping pod kuratelą państwa miał miejsce w NRD, RFN, ZSRR, Chinach, USA, Kenii i w Polsce. Wnioski. W latach 50. XX w. zawodniczki – zwłaszcza w Związku Radzieckim – spo- radycznie przyjmowały testosteron oraz steroidy anaboliczno-androgenne. Później liczba stoso- wanych środków dopingujących systematycznie rosła. Na większą skalę zaczęto je przyjmować dopiero w latach 70. i 80. XX w. Próbą zapanowania nad tym zjawiskiem są badania antydopin- gowe, jednak chęć zwycięstwa często przeważa nad zdrowym rozsądkiem. Słowa kluczowe: sport, doping, historia, kobiety WprowadzEniE Doping w sporcie znany jest od bardzo dawna. Zapewne byłby łatwiejszy do wykrycia, gdyby nie korzyści płynące z niego dla firm farmaceutycznych, lekarzy, trenerów, za- wodników, federacji sportowych oraz polityków i rządów państw.